Optimization of an immunotherapeutic protocol with poly(I,C)-LC

James E Talmadge, Diethelm Hartmann

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

The development of successful immunotherapeutic protocols requires new therapeutic strategies as well as the development of clinically predictive tumor models and protocols. A bell-shaped response curve is observed with many biological response modifiers (BRMs), not only for immunomodulation, but also for therapeutic activity. Although most BRMs, including poly(I,C)-LC, are toxic at high doses, the administration of nontoxic doses by an optimal protocol and route of injection results in significant therapeutic benefit and increased immunodulation in tumor-bearing animals compared to the administration of a maximum tolerated dose (MTD). We suggest that Phase II clinical trials using an optimal immunomodulatory protocol may result in increased therapeutic activity compared to protocols based on the MTD.

Original languageEnglish (US)
Pages (from-to)484-489
Number of pages6
JournalJournal of Biological Response Modifiers
Volume4
Issue number5
StatePublished - Jan 1 1985

Fingerprint

Maximum Tolerated Dose
Immunologic Factors
Phase II Clinical Trials
Immunomodulation
Poisons
Therapeutics
Neoplasms
Injections
polyriboinosinic-polyribocytidylic acid

Keywords

  • Immunotherapy
  • Metastasis
  • Poly(I,C)-LC

ASJC Scopus subject areas

  • Immunology
  • Pharmacology
  • Cancer Research

Cite this

Optimization of an immunotherapeutic protocol with poly(I,C)-LC. / Talmadge, James E; Hartmann, Diethelm.

In: Journal of Biological Response Modifiers, Vol. 4, No. 5, 01.01.1985, p. 484-489.

Research output: Contribution to journalArticle

@article{d6f74f3130e14b338cf50fe8af7f3565,
title = "Optimization of an immunotherapeutic protocol with poly(I,C)-LC",
abstract = "The development of successful immunotherapeutic protocols requires new therapeutic strategies as well as the development of clinically predictive tumor models and protocols. A bell-shaped response curve is observed with many biological response modifiers (BRMs), not only for immunomodulation, but also for therapeutic activity. Although most BRMs, including poly(I,C)-LC, are toxic at high doses, the administration of nontoxic doses by an optimal protocol and route of injection results in significant therapeutic benefit and increased immunodulation in tumor-bearing animals compared to the administration of a maximum tolerated dose (MTD). We suggest that Phase II clinical trials using an optimal immunomodulatory protocol may result in increased therapeutic activity compared to protocols based on the MTD.",
keywords = "Immunotherapy, Metastasis, Poly(I,C)-LC",
author = "Talmadge, {James E} and Diethelm Hartmann",
year = "1985",
month = "1",
day = "1",
language = "English (US)",
volume = "4",
pages = "484--489",
journal = "Journal of Immunotherapy",
issn = "1524-9557",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Optimization of an immunotherapeutic protocol with poly(I,C)-LC

AU - Talmadge, James E

AU - Hartmann, Diethelm

PY - 1985/1/1

Y1 - 1985/1/1

N2 - The development of successful immunotherapeutic protocols requires new therapeutic strategies as well as the development of clinically predictive tumor models and protocols. A bell-shaped response curve is observed with many biological response modifiers (BRMs), not only for immunomodulation, but also for therapeutic activity. Although most BRMs, including poly(I,C)-LC, are toxic at high doses, the administration of nontoxic doses by an optimal protocol and route of injection results in significant therapeutic benefit and increased immunodulation in tumor-bearing animals compared to the administration of a maximum tolerated dose (MTD). We suggest that Phase II clinical trials using an optimal immunomodulatory protocol may result in increased therapeutic activity compared to protocols based on the MTD.

AB - The development of successful immunotherapeutic protocols requires new therapeutic strategies as well as the development of clinically predictive tumor models and protocols. A bell-shaped response curve is observed with many biological response modifiers (BRMs), not only for immunomodulation, but also for therapeutic activity. Although most BRMs, including poly(I,C)-LC, are toxic at high doses, the administration of nontoxic doses by an optimal protocol and route of injection results in significant therapeutic benefit and increased immunodulation in tumor-bearing animals compared to the administration of a maximum tolerated dose (MTD). We suggest that Phase II clinical trials using an optimal immunomodulatory protocol may result in increased therapeutic activity compared to protocols based on the MTD.

KW - Immunotherapy

KW - Metastasis

KW - Poly(I,C)-LC

UR - http://www.scopus.com/inward/record.url?scp=0022351934&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022351934&partnerID=8YFLogxK

M3 - Article

VL - 4

SP - 484

EP - 489

JO - Journal of Immunotherapy

JF - Journal of Immunotherapy

SN - 1524-9557

IS - 5

ER -